<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for PLX</title>
    <link />
    <description>Headlines for Protalix BioTherapeutics, Inc.</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>PLX July Options Begin Trading</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11928670/1/plx-july-options-begin-trading.html.aspx?puc=aol&amp;cm_ven=aol&amp;source=itxwebtxt0000015</link>
      <author>TheStreet</author>
      <pubDate>Mon, 20 May 2013 16:20:00 GMT</pubDate>
    </item>
    <item>
      <title>Protalix BioTherapeutics Treatment for Gaucher Disease Approved in Mexico, Chile</title>
      <link>http://www.fool.com/news/xt/smartmoney/www.smartmoney.com/news/on/.aspx?story=on-20130429-000165&amp;cid=1244&amp;source=itxwebtxt0000015</link>
      <author>Smart Money</author>
      <pubDate>Mon, 29 Apr 2013 08:25:00 GMT</pubDate>
    </item>
    <item>
      <title>Protalix Says COFEPRIS, Public Health Institute of Chile Grant Approval to UPLYSO for Type 1 Gaucher</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/04/3537061/protalix-says-cofepris-public-health-institute-of-chile-grant-approval-to-uplyso-.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Mon, 29 Apr 2013 07:34:26 GMT</pubDate>
    </item>
    <item>
      <title>Update on Protalix Gaucher Study - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96330/update-on-protalix-gaucher-study.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Thu, 04 Apr 2013 16:22:01 GMT</pubDate>
    </item>
    <item>
      <title>5 Stocks Under $10 Set to Soar</title>
      <link>http://www.fool.com/news/xt/thestreet/www.stockpickr.com/5-stocks-under-10-set-soar.html-23.aspx?puc=aol&amp;cm_ven=aol&amp;source=itxwebtxt0000015</link>
      <author>TheStreet</author>
      <pubDate>Thu, 04 Apr 2013 13:53:00 GMT</pubDate>
    </item>
    <item>
      <title>Protalix Expects Phase 1 Trial of PRX112 Complete in Q3</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/04/3463286/protalix-expects-phase-1-trial-of-prx112-complete-in-q3.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Tue, 02 Apr 2013 07:33:13 GMT</pubDate>
    </item>
    <item>
      <title>The Future Of Medicine: A Look At 5 Stem Cell Companies</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1295171-the-future-of-medicine-a-look-at-5-stem-cell-companies.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 22 Mar 2013 11:58:48 GMT</pubDate>
    </item>
    <item>
      <title>Brazil Approves Pfizer-Protalix Gaucher Drug  - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/95283/brazil-approves-pfizer-protalix-gaucher-drug.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Thu, 21 Mar 2013 09:50:01 GMT</pubDate>
    </item>
    <item>
      <title>UPDATE: Pfizer, Protalix Receive ANVISA Approval for UPLYSO in Brazil</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/03/3425501/update-pfizer-protalix-receive-anvisa-approval-for-uplyso-in-brazil.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Mon, 18 Mar 2013 14:18:53 GMT</pubDate>
    </item>
    <item>
      <title>Special Protocol Assessments: The Case Studies</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1217561-special-protocol-assessments-the-case-studies.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 22 Feb 2013 14:31:38 GMT</pubDate>
    </item>
    <item>
      <title>BioMarin Earnings: An Early Look</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/02/19/biomarin-earnings-an-early-look/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Tue, 19 Feb 2013 10:29:00 GMT</pubDate>
    </item>
    <item>
      <title>Protalix Says New Clinical Data on ELELYSO Will Be Presented at WORLD Symposium</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/02/3329497/protalix-says-new-clinical-data-on-elelyso-will-be-presented-at-world-symposium.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Wed, 13 Feb 2013 07:33:01 GMT</pubDate>
    </item>
    <item>
      <title>This Week in Biotech</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/02/09/this-week-in-biotech-14/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Sat, 09 Feb 2013 12:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Protalix Exploring Options - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/92278/protalix-exploring-options.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Thu, 07 Feb 2013 18:15:01 GMT</pubDate>
    </item>
    <item>
      <title>Who's Going to Buy This Orphan Drugmaker?</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/02/06/plx-protalix-strategic-review/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 06 Feb 2013 13:12:00 GMT</pubDate>
    </item>
    <item>
      <title>U.S. HOT STOCKS: Zynga, Take-Two, Shutterfly Active in Late Trading</title>
      <link>http://www.fool.com/news/xt/smartmoney/www.smartmoney.com/news/on/.aspx?story=on-20130205-000557&amp;cid=1244&amp;source=itxwebtxt0000015</link>
      <author>Smart Money</author>
      <pubDate>Tue, 05 Feb 2013 18:26:59 GMT</pubDate>
    </item>
    <item>
      <title>Benzinga's M&amp;A Chatter for Tuesday February 5, 2013</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/trading-ideas/long-ideas/13/02/3307094/benzingas-m-a-chatter-for-tuesday-february-5-2013.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Tue, 05 Feb 2013 17:48:39 GMT</pubDate>
    </item>
    <item>
      <title>Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/earnings/13/02/3306548/mid-afternoon-market-update-markets-edge-toward-record-highs-arch-coal-f.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Tue, 05 Feb 2013 15:57:29 GMT</pubDate>
    </item>
    <item>
      <title>Why Protalix BioTherapeutics Shares Soared</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/02/05/why-protalix-biotherapeutics-shares-soared/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Tue, 05 Feb 2013 15:12:00 GMT</pubDate>
    </item>
    <item>
      <title>U.S. HOT STOCKS: Yum Brands, McGraw-Hill, Virgin Media, Opexa</title>
      <link>http://www.fool.com/news/xt/smartmoney/www.smartmoney.com/news/on/.aspx?story=on-20130205-000423&amp;cid=1244&amp;source=itxwebtxt0000015</link>
      <author>Smart Money</author>
      <pubDate>Tue, 05 Feb 2013 14:05:59 GMT</pubDate>
    </item>
  </channel>
</rss>
